ECSP088477A - Derivados de 3-alquilazetidina sustituidos con heterociclos - Google Patents
Derivados de 3-alquilazetidina sustituidos con heterociclosInfo
- Publication number
- ECSP088477A ECSP088477A EC2008008477A ECSP088477A ECSP088477A EC SP088477 A ECSP088477 A EC SP088477A EC 2008008477 A EC2008008477 A EC 2008008477A EC SP088477 A ECSP088477 A EC SP088477A EC SP088477 A ECSP088477 A EC SP088477A
- Authority
- EC
- Ecuador
- Prior art keywords
- treatment
- disorders
- useful
- compounds
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos novedosos de la fórmula estructural (I) son antagonistas y/o agonistas inversos del receptor canabinoide-1 (CB1) y son útiles en el tratamiento, prevención y supresión de enfermedades mediadas por el receptor CB1. Los compuestos de la presente invención son útiles como fármacos que actúan a nivel central en el tratamiento de psicosis, deficiencias de la memoria, trastornos cognitivos, enfermedad de Alzheimer, migraña, neuropatía, trastornos neuroinflamatorios que incluyen esclerosis múltiple y síndrome de Guillain-Barré y las secuelas inflamatorias de la encefalitis vírica, accidentes vasculares cerebrales, y traumatismo craneal, trastornos de ansiedad, estrés, epilepsia, enfermedad de Parkinson, trastornos del movimiento, y esquizofrenia. Los compuestos también son útiles para el tratamiento de trastornos de abuso de sustancias, para el tratamiento de obesidad o trastornos de la alimentación, así como para el tratamiento de asma, estreñimiento, pseudo-obstrucción intestinal crónica, y cirrosis hepática.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74018305P | 2005-11-28 | 2005-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088477A true ECSP088477A (es) | 2008-06-30 |
Family
ID=37779312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008477A ECSP088477A (es) | 2005-11-28 | 2008-05-27 | Derivados de 3-alquilazetidina sustituidos con heterociclos |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1954692A1 (es) |
KR (1) | KR20080073721A (es) |
AR (1) | AR058199A1 (es) |
BR (1) | BRPI0619018A2 (es) |
CR (1) | CR10014A (es) |
DO (1) | DOP2006000261A (es) |
EC (1) | ECSP088477A (es) |
IL (1) | IL191586A0 (es) |
MA (1) | MA30086B1 (es) |
NO (1) | NO20082919L (es) |
PE (1) | PE20070647A1 (es) |
RU (1) | RU2008126248A (es) |
SV (1) | SV2009002917A (es) |
TW (1) | TW200804317A (es) |
WO (1) | WO2007062193A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
AU2008317482A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Synthesis and crystalline forms of CB-1 antagonist/inverse agonist |
US9440948B2 (en) | 2010-09-03 | 2016-09-13 | University Of Florida Research Foundation, Inc. | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2805817B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
UA83230C2 (ru) * | 2003-06-11 | 2008-06-25 | Мерк Энд Ко., Инк. | Замещенные производные 3-алкил- и 3-алкенилазетидинов |
JP2008540426A (ja) * | 2005-05-02 | 2008-11-20 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び肥満の治療のためのジペプチジルペプチダーゼiv阻害薬及びカンナビノイドcb1受容体拮抗薬の組み合わせ |
-
2006
- 2006-11-20 AR ARP060105076A patent/AR058199A1/es unknown
- 2006-11-22 BR BRPI0619018A patent/BRPI0619018A2/pt not_active IP Right Cessation
- 2006-11-22 TW TW095143274A patent/TW200804317A/zh unknown
- 2006-11-22 RU RU2008126248/04A patent/RU2008126248A/ru not_active Application Discontinuation
- 2006-11-22 KR KR1020087012880A patent/KR20080073721A/ko not_active Application Discontinuation
- 2006-11-22 EP EP06838347A patent/EP1954692A1/en not_active Withdrawn
- 2006-11-22 WO PCT/US2006/045328 patent/WO2007062193A1/en active Application Filing
- 2006-11-23 PE PE2006001495A patent/PE20070647A1/es not_active Application Discontinuation
- 2006-11-23 DO DO2006000261A patent/DOP2006000261A/es unknown
-
2008
- 2008-05-20 IL IL191586A patent/IL191586A0/en unknown
- 2008-05-22 CR CR10014A patent/CR10014A/es not_active Application Discontinuation
- 2008-05-27 EC EC2008008477A patent/ECSP088477A/es unknown
- 2008-05-28 SV SV2008002917A patent/SV2009002917A/es not_active Application Discontinuation
- 2008-06-25 MA MA31075A patent/MA30086B1/fr unknown
- 2008-06-27 NO NO20082919A patent/NO20082919L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2007062193A1 (en) | 2007-05-31 |
DOP2006000261A (es) | 2007-07-15 |
EP1954692A1 (en) | 2008-08-13 |
PE20070647A1 (es) | 2007-08-11 |
IL191586A0 (en) | 2008-12-29 |
SV2009002917A (es) | 2009-02-19 |
KR20080073721A (ko) | 2008-08-11 |
CR10014A (es) | 2008-07-29 |
BRPI0619018A2 (pt) | 2016-11-29 |
MA30086B1 (fr) | 2008-12-01 |
AR058199A1 (es) | 2008-01-23 |
NO20082919L (no) | 2008-08-27 |
RU2008126248A (ru) | 2010-01-10 |
TW200804317A (en) | 2008-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP056207A (es) | Derivados de 3-alquil y 3-alquenilazetidina sustituidos | |
ECSP088477A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos | |
ECSP045289A (es) | Amidas sustituidas | |
DE60316829D1 (de) | Substituierte furoä2,3-büpyridin derivate | |
DE60334787D1 (de) | Substituierte amide | |
WO2003082190A3 (en) | Spirocyclic amides as cannabinoid receptor modulators | |
WO2008024284A3 (en) | Sulfonylated piperazines as cannabinoid-1 receptor modulators | |
WO2003063781A3 (en) | Substituted imidazoles as cannabinoid receptor modulators | |
ATE501151T1 (de) | Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren | |
WO2005027837A3 (en) | Substituted sulfonamides | |
WO2004029204A3 (en) | Substituted pyrimidines | |
WO2004058145A3 (en) | Substituted amides | |
WO2003086288A3 (en) | Bicyclic amides | |
ATE452890T1 (de) | Substituierte naphthyridinonderivate | |
WO2007136607A3 (en) | Substituted esters as cannabinoid-1 receptor modulators | |
WO2003082191A3 (en) | Substituted 2,3-diphenyl pyridines | |
ECSP19043120A (es) | Pirrolopirimidinas como potenciadores de cftr | |
WO2007064566A3 (en) | Heterocycle-substituted 3-alkyl azetidine derivatives | |
WO2006041797A3 (en) | Acyclic hydrazides as cannabinoid receptor modulators | |
CL2008000394A1 (es) | Compuestos derivados de azabicicloalcano; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos asociados a la enfermedad de alzheimer, parkinson, patologias psiquiatricas, accidentes vasculares cerebrales, sindr | |
WO2014014698A3 (en) | Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof | |
DE602006013040D1 (de) | Substituierte pyradinon-derivate als alpha2-adrenorezeptor-antagonisten | |
DOP2004001060A (es) | Compuestos moduladores de cb1 |